MARKET

GTBP

GTBP

Gt Biopharma Inc
NASDAQ
0.7060
-0.0040
-0.56%
Opening 14:26 01/22 EST
OPEN
0.7000
PREV CLOSE
0.7100
HIGH
0.7298
LOW
0.6922
VOLUME
496.42K
TURNOVER
--
52 WEEK HIGH
3.850
52 WEEK LOW
0.5400
MARKET CAP
7.51M
P/E (TTM)
-0.2090
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at GTBP last week (0112-0116)?
Weekly Report · 3d ago
GT Biopharma Submits IND For GTB-5550 TriKE, Targeting B7-H3 Solid Tumors
NASDAQ · 01/15 15:41
GT Biopharma Submits IND For GTB-5550 TriKE To Treat Solid Tumors
NASDAQ · 01/15 14:11
GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE
TipRanks · 01/15 13:36
GT BIOPHARMA ANNOUNCES IND SUBMISSION FOR GTB-5550 TRIKE®, A B7-H3-TARGETED NATURAL KILLER (NK) CELL ENGAGER FOR B7-H3 EXPRESSING SOLID TUMOR CANCERS
Reuters · 01/15 13:30
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
Benzinga · 01/15 13:01
GT Biopharma Announces IND Submission For GTB-5550 TriKE; Reports Preliminary Unaudited Cash Balance Of ~$7M As Of Dec. 31, 2025
Benzinga · 01/15 13:00
More
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Webull offers GT Biopharma Inc stock information, including NASDAQ: GTBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GTBP stock methods without spending real money on the virtual paper trading platform.